Antibodies to neutralising epitopes synergistically block the interaction of the receptor‐binding domain of SARS‐CoV‐2 to ACE 2

OBJECTIVES: A major COVID‐19 vaccine strategy is to induce antibodies that prevent interaction between the Spike protein's receptor‐binding domain (RBD) and angiotensin‐converting enzyme 2 (ACE2). These vaccines will also induce T‐cell responses. However, concerns were raised that aberrant vacc...

Descripción completa

Detalles Bibliográficos
Autores principales: Pandey, Manisha, Ozberk, Victoria, Eskandari, Sharareh, Shalash, Ahmed O, Joyce, Michael A, Saffran, Holly A, Day, Christopher J, Lepletier, Ailin, Spillings, Belinda L, Mills, Jamie‐Lee, Calcutt, Ainslie, Fan, Fan, Williams, James T, Stanisic, Danielle I, Hattingh, Laetitia, Gerrard, John, Skwarczynski, Mariusz, Mak, Johnson, Jennings, Michael P, Toth, Istvan, Tyrrell, D Lorne, Good, Michael F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7937407/
https://www.ncbi.nlm.nih.gov/pubmed/33732459
http://dx.doi.org/10.1002/cti2.1260

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7937407/
https://www.ncbi.nlm.nih.gov/pubmed/33732459
http://dx.doi.org/10.1002/cti2.1260

Ejemplares similares